Defining the natural history of rare genetic liver diseases: Lessons learned from the NAPPED initiative

While rare diseases collectively affect ~300 million people worldwide, the prevalence of each disease concerns a relatively small number of patients. Usually, only limited data with regard to natural history are available. Multicenter initiatives are needed to aggregate data and answer clinically re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of medical genetics 2021-07, Vol.64 (7), p.104245-104245, Article 104245
Hauptverfasser: van Wessel, Daan B.E., Gonzales, Emmanuel, Hansen, Bettina E., Verkade, Henkjan J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:While rare diseases collectively affect ~300 million people worldwide, the prevalence of each disease concerns a relatively small number of patients. Usually, only limited data with regard to natural history are available. Multicenter initiatives are needed to aggregate data and answer clinically relevant research questions. In 2017, we launched the NAtural course and Prognosis of PFIC and Effect of biliary Diversion (NAPPED) consortium. In three years, NAPPED created a global network focused on rare genetic liver diseases in the Progressive Familial Intrahepatic Cholestasis (PFIC) spectrum. During these years, we have learned important lessons which we feel should be taken into account when initiating and leading a global consortium. First, it is essential to ‘keep it simple’ from the start. Research questions, case report forms (CRFs) and data acquisition should be limited and clear to stay focused and keep the workload low for new participants. Secondly, early rewards and research output are needed to keep momentum and motivation. Quick output can only follow a clean and simple design. Thirdly, the leading team should be in touch and accessible. Ideally, an involved PhD-candidate is appointed as primary contact person. Lastly, be inclusive and actively involve all participants the consortium's course. Global consortia are critical for personalized medicine in rare diseases. Also, they are essential for setting up trials to investigate generic drugs and personalized therapies. We hope to herewith stimulate others that are starting (or are planning to start) a global consortium, ultimately to help improve the care for patients with a rare disease. •Global consortia are critical for improving the care of (ultra) rare diseases.•The NAPPED consortium is an example of successful global academic collaboration.•We herewith want to share our ‘lessons learned’. 1. research questions and data acquisition should be limited and clear. 2: early rewards and research output are needed for momentum and motivation. 3: be in touch and be accessible. 4: be inclusive and promote active involvement of consortium participants.
ISSN:1769-7212
1878-0849
DOI:10.1016/j.ejmg.2021.104245